Ventricular Assist Devices: Challenges of the One-device Era
- PMID: 36644648
- PMCID: PMC9820067
- DOI: 10.15420/cfr.2022.01
Ventricular Assist Devices: Challenges of the One-device Era
Abstract
Heart failure (HF) is linked to to high mortality rates and recurrent hospitalisations despite medical and device-based achievements. The use of left ventricular assist devices (LVADs) has improved survival among patients with advanced HF. Significant progress has been achieved with the new generation of continuous-flow devices, particularly with the fully magnetically levitated HeartMate 3. In June 2021, Medtronic announced the abrupt withdrawal of the HeartWare device from the market. This decision has introduced a new era in which the field of mechanical support for advanced HF patients is dominated by a single device - the HeartMate 3. The direct clinical and economic consequences of this change will necessitate new surgical considerations. Because of the expected need for HeartWare device replacement in small patients, new surgical techniques and device adaptation will be needed. The new single-device era will hopefully encourage scientists and engineers to create innovations in the advanced HF arena. Special considerations should be taken during the COVID-19 pandemic when treating patients with LVADs.
Keywords: HeartMate 3; HeartWare; left ventricular assist device; mechanical circulatory support; paediatric mechanical circulatory support.
Copyright © 2022, Radcliffe Cardiology.
Conflict of interest statement
Disclosure: The authors have no conflicts of interest to declare.
References
-
- Ben Avraham B, Crespo-Leiro MG, Filippatos G et al. HFA of the ESC position paper on the management of LVAD supported patients for the non LVAD specialist healthcare provider part 1: introduction and at the non-hospital settings in the community. ESC Heart Fail. 2021;8:4394–408. doi: 10.1002/ehf2.13588. - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous
